Follicular lymphoma is a form of non-Hodgkin lymphoma. It’s usually slow-growing and responds well to treatment but is difficult to cure. Since it is a slow-moving cancer, doctors and patients ...

Follicular lymphoma is a cancer that affects white blood cells called lymphocytes. They help your body fight infections. There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the ...

Treatment for follicular lymphoma is not one-size-fits-all. Many treatments are available for this form of non-Hodgkin's lymphoma. While it may be overwhelming to face so many choices, a wide ...

There have been a number of advancements in the treatment of follicular lymphoma in 2024. In March, the Food and Drug Administration (FDA) approved Brukinsa (zanubrutinib) plus Gazyva (obinutuzumab) ...

Medically reviewed by Gagandeep Brar, MD Stage 4 lymphoma is a cancer of white blood cells called lymphocytes that has spread outside the lymph nodes to other parts of the body. While this is an ...

We’ve long known follicular lymphoma (FL) as a slow-growing, incurable disease that tends to relapse. For many patients, that has meant cycling through treatments over decades, each remission a ...

FDA approves tafasitamab with lenalidomide and rituximab, offering a groundbreaking chemotherapy-free treatment for relapsed ...

Follicular lymphoma is a typically slow-progressing B-cell lymphoproliferative disease that originates from transformed follicular center B cells. It is commonly marked by widespread lymph node ...

The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with ...

Roche has demonstrated the power of combining two of oncology’s hottest modalities—bispecifics and antibody-drug conjugates ...

The husband of a woman who disappeared on Mother’s Day 2020 is set to appear in a Colorado court for the first time since ...

Approval was based on results from the Phase III inMIND trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in patients treated ...